[Advances in studies on selective RXR ligands].
Mei
Jiang-hua
JH
The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Wang
Ming-wei
MW
D000077556:Alitretinoin; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D000077610:Bexarotene; D006801:Humans; D008024:Ligands; D009369:Neoplasms / Q000473:pathology; D047488:Retinoid X Receptors / Q000819:agonists / Q000737:chemistry* / Q000494:pharmacology; D012176:Retinoids / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013764:Tetrahydronaphthalenes / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D014212:Tretinoin / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology
D000970:Antineoplastic Agents; D008024:Ligands; D047488:Retinoid X Receptors; D012176:Retinoids; D013764:Tetrahydronaphthalenes; D000077556:Alitretinoin; D014212:Tretinoin; D000077610:Bexarotene; C100800:ALRT 1550